Zobrazeno 1 - 10
of 20
pro vyhledávání: '"S Fischkoff"'
Autor:
G. Richardson, A.W. Tolcher, M. Morris, P. de Souza, A. Hamid, X.K. She, L. Zhu, S. Zheng, G. Liu, Y. Li, F. Du, S. Fischkoff, H. Gong, J. Zha, P.P. Luo
Publikováno v:
Annals of Oncology. 33:S882-S883
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b0d275def7cf04444b81ca1d2acca54
https://doi.org/10.1016/j.annonc.2022.07.867
https://doi.org/10.1016/j.annonc.2022.07.867
Autor:
G. Richardson, A. Tolcher, F. Parnis, J. Park, A. Hamid, K. She, L. Liu, S. Zheng, G. Liu, X. Li, B. Li, X. Wang, M. Chen, S. Fischkoff, H. Gong, P. Luo
Publikováno v:
Annals of Oncology. 32:S1436-S1437
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a91306a83064783cc4b4375bed58556
https://doi.org/10.1016/j.annonc.2021.10.156
https://doi.org/10.1016/j.annonc.2021.10.156
Autor:
J Sany, L. B. A. Van De Putte, C Atkins, J. W. J. Bijlsma, N Walter, Michel Malaise, L. Settas, Peter Nash, S Fischkoff, M Kaul, S Todesco, Maxime Dougados, P.L.C.M. van Riel, H Kupper, Paul Emery, Anthony S. Russell
Publikováno v:
Annals of the Rheumatic Diseases. 63:508-516
Objective: To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD treatment has failed. Methods: In a 26 week, double blind, placebo controlled, phase III trial, 544 patients with RA were random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a94882d37721bb4014945317a7ea876
https://doi.org/10.1136/ard.2003.013052
https://doi.org/10.1136/ard.2003.013052
Autor:
Sharyn D. Baker, Eric K. Rowinsky, Raja Velagapudi, B Razvillas, S Fischkoff, S. G. Eckhardt, D Toppmeyer, R Fram, D. D. Von Hoff, Maura Kraynak, Lisa A. Hammond, C. Aylesworth, K Jakimowicz, Miguel A. Villalona-Calero
Publikováno v:
Journal of Clinical Oncology. 16:2770-2779
PURPOSE To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic profile of the dolastatin 15 analog LU103793 when administered daily for 5 days every 3 weeks. PATIENTS AND METHODS Fifty-six courses of LU103
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94560091f0a5d0874eaebcbebaa2be28
https://doi.org/10.1200/jco.1998.16.8.2770
https://doi.org/10.1200/jco.1998.16.8.2770
Autor:
T Tuypens, Jan Tavernier, I Fache, Geert Plaetinck, Walter Fiers, S Fischkoff, Rene Devos, J Van der Heyden
Publikováno v:
The Journal of Experimental Medicine
The T cell product interleukin 5 (IL-5) has been shown to be a key factor in the development and the maturation of the eosinophilic cell lineage. We report here on the detection of human IL-5 receptors on eosinophilic sublines of the promyelocytic le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da4c4de4a8ee64e7c29c77ec3b0ad2e4
http://europepmc.org/articles/PMC2188565
http://europepmc.org/articles/PMC2188565
Autor:
Michael H. Weisman, C. Birbara, Harold E. Paulus, E.C. Keystone, Michael E. Weinblatt, Daniel E. Furst, S Fischkoff, Elliot Chartash
Publikováno v:
Speaker abstracts 2001.
Background Objectives To investigate the clinical efficacy and safety of adalimumab (D2E7), given subcutaneously in combination with methotrexate (MTX) to rheumatoid arthritis (RA) patients who are partial responders to MTX treatment. Methods The ARM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01ec011d1520820695da67e2e751f4a9
https://doi.org/10.1136/annrheumdis-2001.1216
https://doi.org/10.1136/annrheumdis-2001.1216
Autor:
Spana C; Palatin Technologies, Inc., Cranbury, New Jersey, USA., Jordan R; Palatin Technologies, Inc., Cranbury, New Jersey, USA., Fischkoff S; Flame Biosciences, New Hope, Pennsylvania, USA.
Publikováno v:
Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Jun; Vol. 24 (6), pp. 1084-1093. Date of Electronic Publication: 2022 Mar 15.
Autor:
Melmed GY; 1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California; 2Department of Medicine, Virginia Commonwealth University, Richmond, Virginia; 3Rochester General Health System, Rochester, New York; 4Baylor College of Medicine, Houston, Texas; 5Department of Medicine, University of Utah, Salt Lake City, Utah; 6Department of Medicine, Vanderbilt University, Nashville, Tennessee; 7Case Western Reserve University, Cleveland, Ohio; 8Innovative Medical Research, Aventura, Florida; 9Department of Medicine, Mt. Sinai Medical Center, New York, New York; 10Department of Medicine, The University of Chicago Medicine, Chicago, Illinois; 11State University of New York at Stony Brook, Stony Brook, New York; 12Section of Digestive Diseases, Yale University, New Haven, Connecticut; 13Department of Medicine, University of California, Irvine, Irvine, California; and 14Celgene Cellular Therapeutics, Warren, New Jersey., Pandak WM, Casey K, Abraham B, Valentine J, Schwartz D, Awais D, Bassan I, Lichtiger S, Sands B, Hanauer S, Richards R, Oikonomou I, Parekh N, Targan S, Johnson K, Hariri R, Fischkoff S
Publikováno v:
Inflammatory bowel diseases [Inflamm Bowel Dis] 2015 Aug; Vol. 21 (8), pp. 1809-16.
Autor:
Baughman RP; University of Cincinnati Medical Center, Cincinnati, OH, USA. BAUGHMRP@UCMAIL.UC.EDU., Culver DA, Jankovi V, Fischkoff S, Brockway G, Lower EE
Publikováno v:
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG [Sarcoidosis Vasc Diffuse Lung Dis] 2015 Jul 22; Vol. 32 (2), pp. 106-14. Date of Electronic Publication: 2015 Jul 22.
Autor:
Ansell SM; Division of Hematology, Mayo Clinic School of Medicine, Rochester, MN 55905, USA. ansell.stephen@mayo.edu, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T, Graziano R, Blanset D, Yellin M, Fischkoff S, Assad A, Borchmann P
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2007 Jul 01; Vol. 25 (19), pp. 2764-9. Date of Electronic Publication: 2007 May 21.